An Early Warning Model for Assessing the Onset, Progression and Sequelae of COVID-19

Sponsor
Xiyuan Hospital of China Academy of Chinese Medical Sciences (Other)
Overall Status
Recruiting
CT.gov ID
NCT05761652
Collaborator
Beijing YouAn Hospital (Other), Kossamak Hospital (Other), Kamuzu University of Health Sciences (Other)
378
1
18
21

Study Details

Study Description

Brief Summary

Based on the characteristics of symptoms, differences in physical and chemical examinations and tests, and characteristics of traditional Chinese medicine (TCM) disease differentiation and syndrome differentiation, the evaluation indicators for the clinical early warning model were screened, and the "three-level early warning mechanism for COVID-19 patients at high risks, with progression to severe cases and sequelae was constructed.

Condition or Disease Intervention/Treatment Phase
  • Other: Observe and record

Detailed Description

Adopt multi-level evidence base architecture, build "multi-source data analysis, feature extraction, multi-level evidence extraction, active The integrated Chinese and Western medicine big data platform integrates the original evidence processing into a multi-level evidence base, comprehensive analysis of The platform will generate a multi-level evidence base by processing the original evidence, analyze the evaluation indexes of New Coronary Pneumonia, select the features, build a deep neural network model, train and validate the model, and establish a high The model is trained and validated, and a three-level early warning model is established for people at high risk of new coronary pneumonia, those who turn serious, and those with sequelae.

Study Design

Study Type:
Observational
Anticipated Enrollment :
378 participants
Observational Model:
Other
Time Perspective:
Cross-Sectional
Official Title:
An Early Warning Model for Assessing the Onset, Progression and Sequelae of COVID-19
Actual Study Start Date :
Dec 1, 2022
Anticipated Primary Completion Date :
Feb 1, 2024
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Modeling group

Other: Observe and record
The general information, environmental indicators, and auxiliary examination indicators of the subjects were observed and recorded, as well as the TCM physical assessment was performed.

Validation group

Other: Observe and record
The general information, environmental indicators, and auxiliary examination indicators of the subjects were observed and recorded, as well as the TCM physical assessment was performed.

Outcome Measures

Primary Outcome Measures

  1. General Data: [Not more than 5 days after the occurrence of the first symptom (or confirmed onset)]

    including age, underlying diseases, body weight, occupation, smoking, alcohol drinking, salt intake and exercise

  2. Environment Indicators: [Not more than 5 days after the occurrence of the first symptom (or confirmed onset)]

    air temperature, humidity, and air quality

  3. Auxiliary Examination Indicators: [Not more than 5 days after the occurrence of the first symptom (or confirmed onset)]

    blood routine (lymphocyte count, lymphocyte/neutrophil ratio), four coagulation items (PT, APTT, TT, FIB), D-Di, C-reactive protein, erythrocyte sedimentation rate, liver function (ALT, AST, ALP), renal function (BUN, Cr), blood glucose, lung CT

  4. TCM based Evaluation: [Not more than 5 days after the occurrence of the first symptom (or confirmed onset)]

    TCM constitution differentiation With reference to the Classification and Determination of Constitutions in TCM issued by the China Association of Traditional Chinese Medicine. There are nine constitution types based on TCM syndrome differentiation

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Meeting the diagnostic criteria of mild and moderate types of COVID-19 disease described in the "Diagnostic and Treatment Protocol for Novel Coronavirus Pneumonia (Trial version 9)" [9];

  2. Age ≥18 years old and ≤90years old;

  3. Not more than 5 days after the occurrence of the first symptom (or confirmed onset);

  4. The subject agrees to participate the study and have signed the informed consent form by paper signature, electronic signature of mobile software or voice authorization.

Exclusion Criteria:
  1. Pregnant or lactating women;

  2. Patients complicated with severe heart, liver, kidney, blood system and other primary diseases and mental disorders.

  3. Patients with disturbance of consciousness, aphasia, dementia and other conditions that prevent them from cooperating with the clinical investigators

  4. Patients with incomplete study data.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Xiyuan Hospital of China Academy of Chinese Medical Sciences Beijin China 100091

Sponsors and Collaborators

  • Xiyuan Hospital of China Academy of Chinese Medical Sciences
  • Beijing YouAn Hospital
  • Kossamak Hospital
  • Kamuzu University of Health Sciences

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Xiyuan Hospital of China Academy of Chinese Medical Sciences
ClinicalTrials.gov Identifier:
NCT05761652
Other Study ID Numbers:
  • 2023XLA003-2
First Posted:
Mar 9, 2023
Last Update Posted:
Mar 9, 2023
Last Verified:
Feb 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Xiyuan Hospital of China Academy of Chinese Medical Sciences
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 9, 2023